194 related articles for article (PubMed ID: 27596331)
1. Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.
Sarabipour S; Hristova K
J Mol Biol; 2016 Oct; 428(20):3903-3910. PubMed ID: 27596331
[TBL] [Abstract][Full Text] [Related]
2. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors.
Del Piccolo N; Sarabipour S; Hristova K
J Biol Chem; 2017 Jan; 292(4):1288-1301. PubMed ID: 27927983
[TBL] [Abstract][Full Text] [Related]
3. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
4. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome.
Lajeunie E; Heuertz S; El Ghouzzi V; Martinovic J; Renier D; Le Merrer M; Bonaventure J
Eur J Hum Genet; 2006 Mar; 14(3):289-98. PubMed ID: 16418739
[TBL] [Abstract][Full Text] [Related]
5. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
Del Piccolo N; Placone J; Hristova K
Biophys J; 2015 Jan; 108(2):272-8. PubMed ID: 25606676
[TBL] [Abstract][Full Text] [Related]
6. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers.
You M; Spangler J; Li E; Han X; Ghosh P; Hristova K
Biochemistry; 2007 Oct; 46(39):11039-46. PubMed ID: 17845056
[TBL] [Abstract][Full Text] [Related]
7. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
8. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
[TBL] [Abstract][Full Text] [Related]
10. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation.
Li E; You M; Hristova K
J Mol Biol; 2006 Feb; 356(3):600-12. PubMed ID: 16384584
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia.
Jerchel IS; Hoogkamer AQ; Ariës IM; Boer JM; Besselink NJM; Koudijs MJ; Pieters R; den Boer ML
Sci Rep; 2019 Feb; 9(1):1875. PubMed ID: 30755670
[TBL] [Abstract][Full Text] [Related]
12. Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging Förster resonance energy transfer.
Sarabipour S; Del Piccolo N; Hristova K
Acc Chem Res; 2015 Aug; 48(8):2262-9. PubMed ID: 26244699
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation.
Lew ED; Bae JH; Rohmann E; Wollnik B; Schlessinger J
Proc Natl Acad Sci U S A; 2007 Dec; 104(50):19802-7. PubMed ID: 18056630
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 transmembrane domain interactions persist in the presence of its extracellular domain.
Sarabipour S; Hristova K
Biophys J; 2013 Jul; 105(1):165-71. PubMed ID: 23823235
[TBL] [Abstract][Full Text] [Related]
16. Role of dimerization efficiency of transmembrane domains in activation of fibroblast growth factor receptor 3.
Volynsky PE; Polyansky AA; Fakhrutdinova GN; Bocharov EV; Efremov RG
J Am Chem Soc; 2013 Jun; 135(22):8105-8. PubMed ID: 23679838
[TBL] [Abstract][Full Text] [Related]
17. The pathogenic A391E mutation in FGFR3 induces a structural change in the transmembrane domain dimer.
Mudumbi KC; Julius A; Herrmann J; Li E
J Membr Biol; 2013 Jun; 246(6):487-93. PubMed ID: 23727984
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases.
Bae JH; Schlessinger J
Mol Cells; 2010 May; 29(5):443-8. PubMed ID: 20432069
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 unliganded dimer stabilization by the juxtamembrane domain.
Sarabipour S; Hristova K
J Mol Biol; 2015 Apr; 427(8):1705-14. PubMed ID: 25688803
[TBL] [Abstract][Full Text] [Related]
20. Transforming fusions of FGFR and TACC genes in human glioblastoma.
Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
